Trial Identifiers
Use the hyperlinks, where available to access additional clinical trial information.
Scientific Title
A phase I/II single arm study on the efficacy of combination Belantamab Mafodotin, Carfilzomib, Dexamethasone in patients with early relapsed multiple myeloma
Cooperative Group
Australasian Myeloma Research Consortium
Commercial Sponsor
GlaxoSmithKline Australia Pty Ltd
Summary
Eligible patients will receive 6 cycles of the combination treatment, BelaMafKd, over the course of a 28 day cycle as tolerated. Belantamab mafodotin and Carfilzomib will be delivered by intravenous (IV) infusion on days 1 and 8 and days 1, 8 and 15 of each cycle, respectively. Oral dexamethasone will be given in weekly intervals.